Published: Jan 11, 2011 4:38 pm
Brand Name:  
Generic Name:  
Code Name: SNS01-T
Company: Senesco
FDA Clinical Phase: 1/2

SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of genes required for programmed cell death. SNS01-T is currently being developed for treatment of multiple myeloma for its potential to induce programmed cell death in cancerous cells.

Clinical Trials:
For a list of clinical trials studying SNS01-T for the treatment of multiple myeloma, see

Related Articles:


  • Les Browne said:

    Please note that SNS01-T is currently in an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to a total of approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of the monoclonal protein (M-protein). The study is actively recruiting at the Mayo Clinic, Rochester, MN, University of Arkansas for Medical Sciences in Little Rock and the Mary Babb Randolph Cancer Center in Morgantown, WV.

  • Beacon Staff said:

    Hello Les,

    Thank you very much for sharing this update. We will modify our entry accordingly.